Disc Medicine, Inc. ((IRON)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Disc Medicine, Inc. is conducting a study titled RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia. The study aims to assess the safety and effectiveness of DISC-0974 in treating anemia in patients with myelofibrosis or myelodysplastic syndrome, conditions that significantly impact quality of life.
The intervention being tested is DISC-0974, a drug administered subcutaneously every four weeks. It is designed to improve anemia symptoms in affected patients.
The study is interventional, with a randomized and sequential model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused.
The study began on March 15, 2022, with the latest update submitted on July 23, 2025. These dates are crucial as they indicate the study’s ongoing nature and the timeline for potential results.
This study update could influence Disc Medicine’s stock performance positively, as successful results may lead to increased investor confidence. It also positions the company competitively within the biotech industry, particularly in the niche market of anemia treatment related to myelofibrosis and myelodysplastic syndromes.
The study is ongoing, with further details available on the ClinicalTrials portal.